SILVER SPRING
Ocrevus cleared for pediatric multiple sclerosis
- Sponsor
- Genentech $RHHBY
- Drug
- Ocrevus · ocrelizumab
- Indication
- relapsing-remitting multiple sclerosis
FDA approved Ocrevus (ocrelizumab) IV infusion for relapsing-remitting multiple sclerosis in pediatric patients aged 10 and older.
What this means
Ocrevus is an intravenous antibody treatment that targets B cells, a type of immune cell involved in multiple sclerosis. The FDA has now approved its use for children aged 10 and older with relapsing-remitting MS, expanding its previous adult-only label. This decision gives younger patients access to a treatment that could help manage their condition and reduce relapses.
Drug Watch — recent news on Ocrevus
- Switching to Subcutaneous Ocrelizumab for MS Could Free 883 Chair Hours in a Year - AJMC
- CHMP Recommends EU Approval for Ocrelizumab in Pediatric Relapsing MS - neurologylive.com
- EU regulators recommend approval of infusion therapy for pediatric MS - Multiple Sclerosis News Today
- EMA Supports Pediatric Expansion of Relapsing MS Therapy - Medscape
- Ocrelizumab Discontinuation After Recurrent Serious Infections in Clinically Stable Primary Progressive Multiple Sclerosis: A Case Report - Cureus
Sponsor Watch — recent news on Genentech
- Merck remigromig DME trial results raise safety concerns
- Roche and Earendil forge $1.5bn bispecific discovery deal
- TDM Reagent Kit Market Forecasts Growth from $2.87B (2026) to $6.96B by 2032, Profiling Abbott, Roche, Danaher, Siemens Healthineers & Thermo Fisher
- Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics
- Pharmaceutical Drug Delivery Market Forecasts Growth from $2.15T (2026) to $2.92T by 2031, Profiling J&J, Pfizer, Roche, BD & Novartis